Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia

References

• American Cancer Society. What is chronic lymphocytic leukemia? [cited 2023 Jan 9]. Available from: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/what-is-cll.html
   Google Scholar
• Gomes LC, Ferrão ALM, Evangelista FCG, et al. Advances in chronic lymphocytic leukemia pharmacotherapy. Biomed Pharmacother. 2018;97:349–358. doi:10.1016/j.biopha.2017.10.105
   PubMed Web of Science ®Google Scholar
• Iovino L, Shadman M. Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape. Curr Treat Options Oncol. 2020;21(4):24. doi:10.1007/s11864-020-0715-5
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363. doi:10.1002/ajh.25638
   PubMed Web of Science ®Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798. doi:10.1038/s41375-019-0602-x
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis. Am J Hematol. 2019;94(5):554–562. doi:10.1002/ajh.25436
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506. doi:10.1182/blood-2014-10-606038
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879. doi:10.3324/haematol.2017.182907
   PubMed Web of Science ®Google Scholar
• Lipsky AH, Farooqui MZH, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571–1578. doi:10.3324/haematol.2015.126672
   PubMed Web of Science ®Google Scholar
• Brown JR, Moslehi J, O'Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–1805. doi:10.3324/haematol.2017.171041
   PubMed Web of Science ®Google Scholar
• Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–2067. doi:10.1182/blood-2014-09-603670
   PubMed Web of Science ®Google Scholar
• Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268–2273. doi:10.1002/cncr.30596
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–87. doi:10.1001/jamaoncol.2014.218
   PubMed Web of Science ®Google Scholar
• Mato AR, Samp JC, Gauthier G, et al. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. Cancer Biol Ther. 2018;19(7):636–643. doi:10.1080/15384047.2018.1449616
   PubMed Web of Science ®Google Scholar
• Hampel PJ, Ding W, Call TG, et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60(11):2712–2719. doi:10.1080/10428194.2019.1602268
   PubMed Web of Science ®Google Scholar
• Hardy-Abeloos C, Pinotti R, Gabrilove J. Ibrutinib dose modifications in the management of CLL. J Hematol Oncol. 2020;13(1):66. doi:10.1186/s13045-020-00870-w
   PubMed Web of Science ®Google Scholar
• Sharman J, Kabadi SM, Clark J, et al. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737–746. doi:10.1111/bjh.16922
   PubMed Web of Science ®Google Scholar
• Goyal RK, Nagar SP, Kabadi SM, et al. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the Medicare population. Cancer Med. 2021;10(8):2690–2702. doi:10.1002/cam4.3855
   PubMed Web of Science ®Google Scholar
• Walker J. Patients struggle with high drug prices – WSJ [cited 2023 Jan 9]. Available from: https://www.wsj.com/articles/patients-struggle-with-high-drug-prices-1451557981
   Google Scholar
• Olszewski AJ, Zullo AR, Nering CR, et al. Use of charity financial assistance for novel oral anticancer agents. J Oncol Pract. 2018;14(4):e221–e228. doi:10.1200/JOP.2017.027896
   PubMed Web of Science ®Google Scholar
• Kaisaeng N, Harpe SE, Carroll NV. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm. 2014;20(7):669–675. doi:10.18553/jmcp.2014.20.7.669
   PubMed Web of Science ®Google Scholar
• Doshi JA, Li P, Pettit AR, et al. Reducing out-of-pocket cost barriers to specialty drug use under Medicare part D: addressing the problem of “too much too soon”. Am J Manag Care. 2017;23(3 Suppl):S39–S45.
   PubMed Web of Science ®Google Scholar
• Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166–174. doi:10.1200/JCO.2016.68.2856
   PubMed Web of Science ®Google Scholar
• Lymphoma Research Foundation. U.S. Food and Drug Administration approves acalabrutinib (CALQUENCE) for chronic lymphocytic leukemia/small lymphocytic lymphoma. Lymphoma Research Foundation [cited 2022 Dec 8]. Available from: https://lymphoma.org/news/u-s-food-and-drug-administration-approves-acalabrutinib-calquence-for-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/
   Google Scholar